Pharmaceuticals.jpg

Pharmaceuticals

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

480-54-6

Retrorsine

480-54-6
90274-24-1

Ractopamine HCl

90274-24-1
751-97-3

Rolitetracycline

751-97-3
13292-46-1

Rifampicin

13292-46-1
65896-16-4

Romifidine

65896-16-4
72559-06-9

Rifabutin

72559-06-9
40341-04-6

Rabenzazole

40341-04-6
80214-83-1

Roxithromycin EP

80214-83-1
25081-93-0

Rivastigmine Related CompoundB USP

25081-93-0
147098-20-2

Rosuvastatin Calcium

147098-20-2
22662-39-1

Rafoxanide

22662-39-1
36791-04-5

Ribavirin USP

36791-04-5
292135-78-5

Roflumilast N-Oxide

292135-78-5
1391052-24-6

3,4-Di(cyclopropylmethoxy) Roflumilast

1391052-24-6
755037-03-7

Regorafenib

755037-03-7
524-40-3

Ricinine

524-40-3
NA

Retinyl Acetate USP

NA
84449-90-1

Raloxifene

84449-90-1
15503-86-3

Retrorsine N-Oxide

15503-86-3
139306-10-8

Rivastigmine Related CompoundC

139306-10-8